Previous 10 |
55.2% improvement in baseline pain scores versus 2.3% for the control group 46.4% reduction in breakthrough pain medication, including opioids, versus 1.5% versus for the treatment group PainShield™ had no adverse events or complications and was deemed both safe and ef...
ELMSFORD, N.Y., Dec. 27, 2018 (GLOBE NEWSWIRE) -- NanoVibronix, Inc., (NASDAQ: NAOV) , a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it has expanded its distribution agreement with MDS....
News, Short Squeeze, Breakout and More Instantly...
NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the University of Michigan will begin the pilot phase of its clinical tri...
NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix,” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has ent...
Distribution Partner, Delta Medical, Awarded a Five-Year Federal Supply Schedule Contract for PainShield by Department of Veterans Affairs NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix,” or the “Company”), a medical device company that produces the UroShie...